

Technology Advisory Committee D Interests Register

Upadacitinib for previously treated severe active rheumatoid arthritis [ID1400]

Publication Date: 09/12/2020

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor David Meads	TAC D Committee member	Indirect financial	Part of his team has received research funding from the company to conduct a trial in haematology	NA	06/12/2019	NA	It was agreed that this declaration would not prevent Professor Meads from participating in this section of the meeting.
Dr Matt Bradley	TAC D Committee member	Direct financial	His company has a medicine in Phase 3 development for rheumatoid arthritis that could be a potential competitor to upadacitinib in the future.	NA	06/12/2019	NA	It was agreed that this declaration would not prevent Dr Bradley from participating in this discussion.
Dr Matt Bradley	TAC D Committee member	Non-financial personal	His company is developing a medicine for rheumatoid arthritis. Due to the timings of the work and the timelines for the related NICE appraisals he feels it is unlikely that he or the company can benefit from any knowledge gained from this appraisal.	NA	28/08/2019	NA	It was agreed that the initial conflict would not prevent Dr Bradley from participating in the second discussion of this topic.

Christopher Edwards	Clinical expert	Direct financial	he has received honoraria for attending advisory boards, speaker's bureau and received research support from companies including AbbVie.	NA	23/05/2019	NA	It was agreed that this declaration would not prevent Mr Edwards from participating in this discussion.
---------------------	-----------------	------------------	--	----	------------	----	---